ArticleNanophotonics (Berlin, Germany)2022
Quantitative and sensitive detection of alpha fetoprotein in serum by a plasmonic sensor.
Article in Nanophotonics (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative molecular detection based on surface-enhanced Raman spectroscopy (SERS) is still a great challenge because of the highly nonuniform distribution of the SERS hot spots and the nondeterministic spatial and spectral overlap of the analyte with the hot spot. Here, we report a nanoparticle-on-mirror plasmonic sensor excited by surface plasmon polaritons for quantitative SERS detection of alpha fetoprotein in serum with ultrahigh sensitivity. The uniform gaps between the nanoparticles and gold film and the alignment of the gap modes relative to the excitation electric field endow this substrate with a uniform and strong SERS enhancement. The limit of detection reaches 1.45 fM, 697 times higher than that under normal excitation and 7800 times higher than a commercial enzyme-linked immunosorbent assay kit. This approach offers a potential solution to overcome the bottleneck in the field of SERS-based biosensing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.